Movement Alert｜INNOVENT BIO Rises 8.89% in Regular Trading, H1 Net Profit Surges 50% with 2030 Revenue Target of RMB 35-40 Billion

Market Focus08-26 09:31

On August 26, INNOVENT BIO rose 8.89% in regular trading, trading at HKD 108.9/share, with turnover of HKD 195 million. The rally was driven by the company's strong interim results released on August 25 and a notable institutional stake increase.

According to the mid-year earnings report, INNOVENT BIO posted total revenue of RMB 8.62 billion for H1, up 44.8% year-over-year, with product revenue reaching RMB 8.2 billion, surging 56.7%. IFRS net profit came in at RMB 1.25 billion, representing a 50.2% increase, already surpassing full-year profit levels. Gross margin stood at 85.0%. The company now has 20 marketed products, 13 of which are included in China's National Reimbursement Drug List. Management set a 2030 revenue target of RMB 35-40 billion.

Separately, JP Morgan increased its holdings by approximately 2.36 million shares on August 20 at an average price of HKD 102.24 per share, raising its stake to 5.06%. Multiple investment banks, including Morgan Stanley, Goldman Sachs, and Citi, have maintained buy ratings with target prices ranging from HKD 111.68 to HKD 138.5.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153624912?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-26 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153624912","market":"us","top_or_hot":-1,"title":"Movement Alert｜INNOVENT BIO Rises 8.89% in Regular Trading, H1 Net Profit Surges 50% with 2030 Revenue Target of RMB 35-40 Billion","media":"Market Focus","content":"<p><p>On August 26, INNOVENT BIO rose 8.89% in regular trading, trading at HKD 108.9/share, with turnover of HKD 195 million. The rally was driven by the company's strong interim results released on August 25 and a notable institutional stake increase.</p><p>According to the mid-year earnings report, INNOVENT BIO posted total revenue of RMB 8.62 billion for H1, up 44.8% year-over-year, with product revenue reaching RMB 8.2 billion, surging 56.7%. IFRS net profit came in at RMB 1.25 billion, representing a 50.2% increase, already surpassing full-year profit levels. Gross margin stood at 85.0%. The company now has 20 marketed products, 13 of which are included in China's National Reimbursement Drug List. Management set a 2030 revenue target of RMB 35-40 billion.</p><p>Separately, JP Morgan increased its holdings by approximately 2.36 million shares on August 20 at an average price of HKD 102.24 per share, raising its stake to 5.06%. Multiple investment banks, including Morgan Stanley, Goldman Sachs, and Citi, have maintained buy ratings with target prices ranging from HKD 111.68 to HKD 138.5.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INNOVENT BIO Rises 8.89% in Regular Trading, H1 Net Profit Surges 50% with 2030 Revenue Target of RMB 35-40 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INNOVENT BIO Rises 8.89% in Regular Trading, H1 Net Profit Surges 50% with 2030 Revenue Target of RMB 35-40 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-26 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 26, INNOVENT BIO rose 8.89% in regular trading, trading at HKD 108.9/share, with turnover of HKD 195 million. The rally was driven by the company's strong interim results released on August 25 and a notable institutional stake increase.</p><p>According to the mid-year earnings report, INNOVENT BIO posted total revenue of RMB 8.62 billion for H1, up 44.8% year-over-year, with product revenue reaching RMB 8.2 billion, surging 56.7%. IFRS net profit came in at RMB 1.25 billion, representing a 50.2% increase, already surpassing full-year profit levels. Gross margin stood at 85.0%. The company now has 20 marketed products, 13 of which are included in China's National Reimbursement Drug List. Management set a 2030 revenue target of RMB 35-40 billion.</p><p>Separately, JP Morgan increased its holdings by approximately 2.36 million shares on August 20 at an average price of HKD 102.24 per share, raising its stake to 5.06%. Multiple investment banks, including Morgan Stanley, Goldman Sachs, and Citi, have maintained buy ratings with target prices ranging from HKD 111.68 to HKD 138.5.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1153624912","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153624912","pubTimestamp":1787707875,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 26, INNOVENT BIO rose 8.89% in regular trading, trading at HKD 108.9/share, with turnover of HKD 195 million. The rally was driven by the company's strong interim results released on August...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动向提醒|信达生物常规交易上涨8.89%，上半年净利润飙升50%，2030年营收目标350-400亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On August 26, INNOVENT BIO rose 8.89% in regular trading, trading at HKD 108.9/share, with turnover of HKD 195 million. The rally was driven by the company's strong interim results released on August 25 and a notable institutional stake increase.According to the mid-year earnings report, INNOVENT BIO posted total revenue of RMB 8.62 billion for H1, up 44.8% year-over-year, with product revenue reaching RMB 8.2 billion, surging 56.7%. IFRS net profit came in at RMB 1.25 billion, representing a 50.2% increase, already surpassing full-year profit levels. Gross margin stood at 85.0%. The company now has 20 marketed products, 13 of which are included in China's National Reimbursement Drug List. Management set a 2030 revenue target of RMB 35-40 billion.Separately, JP Morgan increased its holdings by approximately 2.36 million shares on August 20 at an average price of HKD 102.24 per share, raising its stake to 5.06%. Multiple investment banks, including Morgan Stanley, Goldman Sachs, and Citi, have maintained buy ratings with target prices ranging from HKD 111.68 to HKD 138.5.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153624912","isCrawlerRequest":true}